Sugi Predict

Sugi Predict / Compounds / SCHEMBL11909455

SCHEMBL11909455

SCHEMBL11909455

CC(C)(C)[Si](C)(C)Oc1cccc(-c2n[nH]c3ncnc(N)c23)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 12/20 0.42
▸ PIK3CA P42336 12/20 0.42
▸ PIK3CB P42338 12/20 0.42
▸ PIK3CG P48736 12/20 0.42
▸ PRKDC P78527 12/20 0.42
▸ SRC P12931 7/20 0.40
▸ ABL1 P00519 5/20 0.40
▸ EGFR P00533 2/20 0.40
▸ HCK P08631 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ MTOR P42345 1/20 0.40
▸ EPHB4 P54760 1/20 0.40
▸ PI4KB Q9UBF8 1/20 0.40
▸ MAP4K4 O95819 3/20 0.36
▸ CDK1 P06493 1/20 0.35
▸ ABL2 P42684 1/20 0.35
▸ NUDT14 O95848 1/20 0.35
▸ NUDT5 Q9UKK9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11908397 0.86 PREP (0.40) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL17331452 0.83 PIK3CD (0.37) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL145785 0.83 SRC (0.56) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL15276905 0.82 PIK3CD (0.45) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL19414398 0.81 MAP4K4 (0.54) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL11908767 0.81 SRC (0.43) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL11149 0.80 BTK (0.51) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL21364711 0.80 MAP4K4 (0.52) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL30387716 0.80 PIK3CD (0.65) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL20793606 0.79 KDM4E (0.47) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10028959-B2 Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors RESPIVERT LTD. (GB) 2018-07-24 — — US disclosed
US-20180118754-A1 COMPOUNDS RESPIVERT LTD. (GB) 2018-05-03 — — US disclosed
US-9834560-B2 Compounds RESPIVERT LTD. (GB) 2017-12-05 — — US disclosed
EP-2825202-B1 STABILIZATION OF PHARMACEUTICAL COMPOSITIONS RESPIVERT LTD (GB) 2017-09-06 — — EP disclosed
US-20170239256-A1 CRYSTALLINE Pl3 KINASE INHIBITORS RESPIVERT LIMITED (GB) 2017-08-24 — — US disclosed
US-20170202841-A1 QUINAZOLIN-4 (3H)-ONE DERIVATIVES USED AS P13 KINASE INHIBITORS RESPIVERT LIMITED (GB) 2017-07-20 — — US disclosed
US-9642799-B2 Crystalline 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-0X0-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide Respivert, Ltd. (GB) 2017-05-09 — — US disclosed
US-9637494-B2 Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors Respivert, Ltd. (GB) 2017-05-02 — — US disclosed
US-20160264583-A1 COMPOUNDS RESPIVERT LTD. (GB) 2016-09-15 — — US disclosed
EP-2834244-B1 CRYSTALLINE PI3 KINASE INHIBITORS RESPIVERT LTD (GB) 2016-08-10 — — EP disclosed
EP-2834244-A1 CRYSTALLINE PI3 KINASE INHIBITORS Respivert Limited (GB) 2015-02-11 — — EP disclosed
EP-2825202-A1 NOVEL PHARMACEUTICAL FORMULATIONS Respivert Limited (GB) 2015-01-21 — — EP disclosed
EP-2630149-B1 QUINAZOLIN-4(3H)-ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS RESPIVERT LTD (GB) 2014-12-24 — — EP disclosed
US-20140249164-A1 COMPOUNDS RESPIVERT LTD (GB) 2014-09-04 — — US disclosed
US-8741909-B2 PI3 kinase inhibitors RESPIVERT LTD. (GB) 2014-06-03 — — US disclosed
EP-2491037-B1 QUINAZOLIN-4(3H)-ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS RESPIVERT LTD (GB) 2014-04-30 — — EP disclosed
WO-2013136076-A1 CRYSTALLINE PI3 KINASE INHIBITORS RESPIVERT LIMITED (GB) 2013-09-19 — — WO disclosed
WO-2013136075-A1 NOVEL PHARMACEUTICAL FORMULATIONS RESPIVERT LIMITED (GB) 2013-09-19 — — WO disclosed
US-20130231355-A1 QUINAZOLIN-4 (3H)- ONE DERIVATIVES USED AS P13 KINASE INHIBITORS RESPIVERT LIMITED (US) 2013-09-05 — — US disclosed
US-20120208799-A1 COMPOUNDS RESPIVERT LTD (GB) 2012-08-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028959-B2 Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors MAP3K13, IRAK3, MAP3K3 PIK3CD 137/4885PIK3CA 85/4885PIK3CB 97/4885
US-20160264583-A1 COMPOUNDS LTC4S, CYP11B2, LTB4R2 PIK3CD 4224/4885PIK3CA 3148/4885PIK3CB 3673/4885
US-20170239256-A1 CRYSTALLINE Pl3 KINASE INHIBITORS PLK3, PLK4, PLK2 PIK3CD 240/4885PIK3CA 209/4885PIK3CB 271/4885
US-20140249164-A1 COMPOUNDS LTC4S, CYP11B2, LTB4R2 PIK3CD 4224/4885PIK3CA 3148/4885PIK3CB 3673/4885
US-20170202841-A1 QUINAZOLIN-4 (3H)-ONE DERIVATIVES USED AS P13 KINASE INHIBITORS MAP3K13, IRAK3, MAP3K3 PIK3CD 137/4885PIK3CA 85/4885PIK3CB 97/4885
US-20120208799-A1 COMPOUNDS LTC4S, CYP11B2, LTB4R2 PIK3CD 4224/4885PIK3CA 3148/4885PIK3CB 3673/4885
US-20130231355-A1 QUINAZOLIN-4 (3H)- ONE DERIVATIVES USED AS P13 KINASE INHIBITORS MAP3K13, IRAK3, MAP3K3 PIK3CD 137/4885PIK3CA 85/4885PIK3CB 97/4885
US-20180118754-A1 COMPOUNDS LTC4S, CYP11B2, LTB4R2 PIK3CD 4224/4885PIK3CA 3148/4885PIK3CB 3673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.